Caris Life Sciences (CAI) Q3 2025 results furnished via 8‑K

Caris Life Sciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Caris Life Sciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025.

The release, dated November 5, 2025, is provided as Exhibit 99.1 and is incorporated by reference solely for Item 2.02. The company states this information is furnished, not filed, under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Caris Life Sciences (CAI) announce in this 8‑K?

The company announced that it issued a press release with financial results for the quarter ended September 30, 2025.

When was the Caris Life Sciences press release issued?

The press release was issued on November 5, 2025.

Which period do the results cover for CAI?

The results cover the quarter ended September 30, 2025.

Where can I find the detailed results for CAI?

They are included in Exhibit 99.1 to this report.

Is the information considered filed or furnished?

The company states the information is furnished, not filed, under the Exchange Act.

What exhibits are attached to this report?

Exhibit 99.1 (Press Release issued November 5, 2025) and Exhibit 104 (Cover Page Inline XBRL).

What is Caris Life Sciences’ trading symbol and exchange?

The common stock trades under CAI on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:17 PM Learn about SEC filing dates

0002019410FALSE00020194102025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2025

CARIS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Texas

001-42706

85-2077369

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

750 W. John Carpenter Freeway Suite 800  Irving, TX						75039
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (866) 771-8946

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CAI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On November 05, 2025, Caris Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein solely for purposes of this Item 2.02 disclosure.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release issued November 5, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2025
			CARIS LIFE SCIENCES, INC.
			By:			/s/ Luke Power
			Name:			Luke Power
			Title:			Senior Vice President, Chief Financial Officer and Chief Accounting Officer